Table 1 List of c-Met inhibitors
From: Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
Drug | Study | Phase |
|---|---|---|
Crizotinib (PF0234I066) | NCT00585I95 | I |
Cabozantinib (XL184) | NCT0I8664I0 | II |
NCT0I708954 | II | |
NCT00940225 | II | |
Foretinib (GSKI363089) | NCT0I068587 | I/II |
Tepotinib (EMDI2I4063) | NCT02864992 | II |
Rilotumumab (AMG102) | NCT02137343 | III |
Ficlatuzumab | NCT03422536 | II |
Tivantinib (ARQ197) | NCT01244191 | III |
Capmatinib (INC280, INCB28060) | NCT0I324479 | I |
NCT0I60336 | II |